Who gets Alzheimer's drugs? Race, vulnerability and health status shape access
The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients have the same opportunity to receive these treatments.
A new study reveals disparities in who receives Alzheimer's disease drugs, with Black and Hispanic adults facing lower odds compared to non-Hispanic white adults. Researchers from Michigan Medicine found that 86% and 79% fewer Black and Hispanic patients, respectively, received anti-amyloid medication than their white counterparts.
The study, published in Neurology, highlights potential disparities in access to these treatments as their use expands. Experts emphasize the need to understand and address these disparities to ensure more patients benefit from the newest therapies.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
